Allogene Therapeutics, Inc. — Form 8-K
Filed August 12, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Allogene reported interim Phase 2 ALPHA3 data for cemacabtagene ansegedleucel (cema-cel) in first-line large B-cell lymphoma: 58.3% (7/12) of patients achieved MRD negativity vs. 16.7% (2/12) in observation arm—a 41.6% absolute difference. The FDA granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations in July 2026. The company accelerated site activation to 100 sites by year-end (6 months ahead of schedule), expects enrollment completion by end of 2027, and next update in mid-2027. Cash position strengthened to $423.6M as of June 30, 2026, projecting runway into 2029.
Why this rating
Interim efficacy signal (41.6% MRD differential) plus FDA breakthrough designations materially de-risk lead program and validate strategy. Site acceleration and cash runway support execution. At $184M market cap, this represents a pivotal inflection for a clinical-stage company, but interim data carries execution and durability risk.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.